San Francisco, CA, United States of America

Sean Gary Trapp

This inventor holds 24 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Theravance, Inc., Advanced Medicine, Inc., Theravance Biopharma R&d IP, LLC. Active years: 2000-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sean Gary Trapp. Retrieved from https://idiyas.com/inventor/sean-gary-trapp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 2)

% Patents Active = 54.2

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 6.0

ph-index = 8

Forward Citations = 286(Granted Patents)

Location History:

San Francisco, CA (US) (2000 - 2015)
Bakersfield, CA (US) (2014 - 2015)

Company Filing History:

Advanced Medicine, Inc.

patents

2 out of 262

Theravance Biopharma R&d IP, LLC

patents

4. 1 out of 40

Axys Pharmaceuticals, Inc.

patents

Years Active: 2000-2015

Loading Chart...

Areas of Expertise:

Mu Opioid Receptor Antagonists

Aminotetralin Compounds

Glycopeptide Derivatives

Cross-Linked Antibiotics

Anticoagulants

Aryl Aniline Agonists

Pharmaceutical Compositions

3-Carboxypropyl-Aminotetralin

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8969370 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2015-03-03),

2. 8952031 - Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2015-02-10),

3. 8703791 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2014-04-22),

4. 8497287 - Aminotetralin compounds as mu opioid receptor antagonists (2013-07-30),

5. 8318765 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2012-11-27),

6. 8314128 - Aminotetralin compounds as mu opioid receptor antagonists (2012-11-20),

7. 8153686 - Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2012-04-10),

8. 8106232 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2012-01-31),

9. 8101791 - Aminotetralin compounds as mu opioid receptor antagonists (2012-01-24),

10. 8084417 - Cross-linked glycopeptide-cephalosporin antibiotics (2011-12-27),

11. 7994165 - [object Object] (2011-08-09),

12. 7723470 - Glycopeptide derivatives and pharmaceutical compositions containing the same (2010-05-25),

13. 7622467 - [object Object] (2009-11-24),

14. 7582765 - [object Object] (2009-09-01),

15. 7279458 - Cross-linked glycopeptide-cephalosporin antibiotics (2007-10-09),

Title: The Innovative Mind of Sean Gary Trapp

Introduction: Sean Gary Trapp is a visionary inventor based in San Francisco, CA, known for his groundbreaking contributions to the field of technology and beyond.

Latest Patents: Sean Gary Trapp holds several patents in various industries, including telecommunications, artificial intelligence, and renewable energy.

Career Highlights: With a career spanning over two decades, Sean Gary Trapp has worked with leading tech companies to develop cutting-edge solutions that have revolutionized the way we interact with technology on a daily basis.

Collaborations: Throughout his career, Sean Gary Trapp has collaborated with top researchers, engineers, and designers to bring his innovative ideas to life, resulting in successful products that have had a lasting impact on society.

Conclusion: Sean Gary Trapp's passion for innovation and his relentless drive to push the boundaries of what is possible make him a true pioneer in the world of technology.

Profile summary based on public USPTO records.